July 2014

ACRO backs COMPETE Act to expand R&D tax credit

Thursday, July 31, 2014

On the eve of Congress’ summer departure, an R&D tax credit bill called the COMPETE Act was introduced this morning that would make the R&D tax credit permanent, increase the credit rate to 25% of qualifying research investments and enable investors in small research companies to claim the credit.

[Read More]

FDA expands approved use of Imbruvica for CLL

Thursday, July 31, 2014

The FDA has expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a Breakthrough Therapy Designation for this use.

[Read More]